# EML4-ALK kinase inhibitor 1

| Cat. No.:<br>CAS No.:<br>Molecular Formula:<br>Molecular Weight:<br>Target:<br>Pathway: | HY-111752<br>1373409-08-5<br>C <sub>31</sub> H <sub>48</sub> N <sub>8</sub> O <sub>3</sub><br>580.76<br>ALK<br>Protein Tyrosine Kinase/RTK              | $H_2N$ $O$ $H$ $O$ $N$ |
|---|---|--|
| Storage:  | -20°C, sealed storage, away from moisture and light<br>* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture<br>and light) |  |

## SOLVENT & SOLUBILITY

| In Vitro | DMSO : 110 mg/mL (189.41 mM; Need ultrasonic)  |                                  |           |           |            |  |  |
|----------|--|----------------------------------|-----------|-----------|------------|--|--|
|          | Preparing<br>Stock Solutions   | Mass<br>Solvent<br>Concentration | 1 mg      | 5 mg      | 10 mg      |  |  |
|          |  | 1 mM                             | 1.7219 mL | 8.6094 mL | 17.2188 mL |  |  |
|          |  | 5 mM                             | 0.3444 mL | 1.7219 mL | 3.4438 mL  |  |  |
|          |  | 10 mM                            | 0.1722 mL | 0.8609 mL | 1.7219 mL  |  |  |
|          | Please refer to the solubility information to select the appropriate solvent.  |                                  |           |           |            |  |  |
| In Vivo  | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5.5 mg/mL (9.47 mM); Clear solution            |                                  |           |           |            |  |  |
|          | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)<br>Solubility: 5.5 mg/mL (9.47 mM); Suspended solution; Need ultrasonic |                                  |           |           |            |  |  |

| <b>BIOLOGICAL ACTIV</b>   |  |
|---------------------------|--|
|                           |  |
| Description               | EML4-ALK kinase inhibitor 1 is a potent orally active inhibitor of echinoderm microtubule-associated protein-like 4-<br>anaplastic lymphoma kinase (EML4-ALK), with an IC <sub>50</sub> of 1 nM <sup>[1]</sup> . |
| IC <sub>50</sub> & Target | IC50: 1 nM (EML4-ALK) <sup>[1]</sup> .   |

#### REFERENCES

[1]. likubo K, et al. Synthesis and structure-activity relationships of pyrazine-2-carboxamide derivatives as novel echinoderm microtubule-associated protein-like 4 (EML4)anaplastic lymphoma kinase (ALK) inhibitors. Bioorg Med Chem. 2019 Apr 15;27(8):1683-1692.

# Product Data Sheet



### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA